GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (STU:BJX1) » Definitions » Float Percentage Of Total Shares Outstanding

BioLife Solutions (STU:BJX1) Float Percentage Of Total Shares Outstanding : 67.30% (As of Jul. 18, 2025)


View and export this data going back to 2017. Start your Free Trial

What is BioLife Solutions Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioLife Solutions's float shares is 32.20 Mil. BioLife Solutions's total shares outstanding is 47.84 Mil. BioLife Solutions's float percentage of total shares outstanding is 67.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioLife Solutions's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioLife Solutions's Institutional Ownership is 62.45%.


BioLife Solutions Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioLife Solutions's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=32.20/47.84
=67.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions Business Description

Industry
Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

BioLife Solutions Headlines

No Headlines